EMJ Oncology 9.7 2021

In this supplement to EMJ Oncology, four leading researchers, Frederik Marmé, Christina Fotopoulou, Ursula Matulonis, and David Bowtell, discussed the impact of late diagnosis and delayed treatment on patient outcomes in ovarian cancer, genetic screening, and risk-reduction strategies.  The evolving landscape of homologous recombination deficiency (HRD) testing and the importance of HRD testing at diagnosis are also explored.